Chinese Phase 2 biotech developing therapies for T cell-driven inflammatory diseases.
Industry: Health Care
First Day Return: +8.8%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 02/26/2021 |
Offer Price | $17.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 11.3 |
Deal Size ($mm) | $191 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 03/18/2021 |
Offer Price | IPO Intelligence Only |
Price Range | IPO Intelligence Only |
Offer Shares (mm) | IPO Intelligence Only |
Deal Size ($mm) | $191 |
Lock-Up Date | IPO Intelligence Only |
Street Research | IPO Intelligence Only |
Underwriters |
---|
IPO Intelligence Only |
Company Data | |
---|---|
Headquarters | Taicang, China |
Founded | 2012 |
Employees at IPO | 62 |
Website www.connectbiopharm.com |